

# Immune monitoring in pancreatic cancer

Gepubliceerd: 20-12-2016 Laatst bijgewerkt: 19-03-2025

analysis of the systemic (blood) and local (tumor tissue) immune parameters in patients with pancreatic cancer and during conventional therapies could reveal new insights in the interplay of these treatment modalities with the immune system and...

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON27380

### Bron

NTR

### Aandoening

pancreatic cancer  
alvleesklierkanker

### Ondersteuning

**Primaire sponsor:** Foundation for Liver and Gastrointestinal Research (SLO)

**Overige ondersteuning:** Foundation for Liver and Gastrointestinal Research (SLO)

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

- To determine the baseline immune signature in pancreatic cancer patients.

# Toelichting onderzoek

## Achtergrond van het onderzoek

Patients diagnosed with pancreatic cancer have a poor survival. There is a strong need for new therapeutic approaches. The presence of pancreatic cancer is known to affect the functionality of the immune system and furthermore chemotherapy (CTx) and (chemo)radiotherapy (CRTx) can subvert immunosuppressive mechanisms, or elicit immune responses by immunogenic cell death of cancer cells. In depth analysis of the systemic (blood) and local (tumor tissue) immune parameters in patients with pancreatic cancer and during conventional therapies could reveal new insights in the interplay of these treatment modalities with the immune system and provide a basis/rationale for new (immuno)therapeutic approaches and combination therapies, e.g. including immune checkpoint blockade, adoptive immune therapies, Toll like receptors agonist and interferons in the current standard of care treatments.

## Doel van het onderzoek

analysis of the systemic (blood) and local (tumor tissue) immune parameters in patients with pancreatic cancer and during conventional therapies could reveal new insights in the interplay of these treatment modalities with the immune system and provide a basis/rationale for new (immuno)therapeutic approaches and combination therapies.

## Onderzoeksopzet

In general we will obtain a baseline sample from every patient (e.g. before surgery or before start of treatment) followed by several samples during their treatment course based on start of therapy and follow-up after each cycle of CTx and/or RTx (maximized at 11 timepoint in total).

## Onderzoeksproduct en/of interventie

Blood collection

# Contactpersonen

## Publiek

's-Gravendijkwal 230  
C.H.J. van Eijck  
Surgery department Erasmus MC  
Rotterdam 3000 CA

The Netherlands  
+31 10 703 3854

## **Wetenschappelijk**

's-Gravendijkwal 230  
C.H.J. van Eijck  
Surgery department Erasmus MC  
Rotterdam 3000 CA  
The Netherlands  
+31 10 703 3854

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

- Age ≥ 18 years
- Diagnosed with resectable or borderline resectable pancreatic cancer, locally advanced pancreatic cancer or metastasized pancreatic cancer
- Planned treatment with either of the currently available standard of care treatments for pancreatic cancer (e.g. surgery, gemcitabine, FOLFIRINOX and/or radiotherapy)
- Signed informed consent

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

- Unable to draw blood for study purposes
- Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator.

## **Onderzoeksopzet**

## Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	N.v.t. / één studie arm
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

## Deelname

Nederland	
Status:	Werving gestart
(Verwachte) startdatum:	01-10-2016
Aantal proefpersonen:	200
Type:	Verwachte startdatum

## Ethische beoordeling

Positief advies	
Datum:	20-12-2016
Soort:	Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 45549  
Bron: ToetsingOnline  
Titel:

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

## In overige registers

Register	ID
NTR-new	NL6173

<b>Register</b>	<b>ID</b>
NTR-old	NTR6320
CCMO	NL59131.078.16
OMON	NL-OMON45549

## Resultaten